{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T03:43:45Z","timestamp":1770349425678,"version":"3.49.0"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Adult growth hormone deficiency (AGHD) is associated with a high prevalence of metabolic syndrome (MS), which contributes to the unfavorable cardiovascular risk profile in these patients. Insulin like growth factor-1 (IGF-1) is a widely used biomarker, however it does not always reflect the cardiometabolic risk and has a poor relationship with clinical efficacy endpoints. Consequently, there is an unmet need for biomarkers to monitor responses to GH-replacement. Afamin is a hormone-like glycoprotein, expressed in the liver. Higher afamin levels are strongly associated with MS and insulin resistance (IR). Although both MS and IR are very common in AGHD, afamin has not been investigated in these patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To investigate afamin as a potential biomarker in patients with AGHD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>Participants included 20 AGHD patients (11 GH-substituted and 9 GH-unsubstituted) and 37 healthy controls. Subjects underwent routine laboratory examinations, anthropometric measurements, body composition analysis using multi-frequency bioelectrical impedance analysis (InBody720) and measurement of serum afamin concentrations. In GH-substituted subjects, GH-substitution was withdrawn for 2 months. Measurements were carried out right before GH-withdrawal, at the end of the 2-month withdrawal period, and 1 month after reinstituting GH-replacement therapy (GHRT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>GH-unsubstituted patients demonstrated higher afamin levels compared to controls (p=0.03). Afamin positively correlated with skeletal muscle mass, bone mineral content, total body water, extracellular- and intracellular water content, insulin (all, p&amp;lt;0.01), HOMA-IR (p=0.01) and C-peptide (p=0.03) levels in AGHD but not in healthy controls. In GH-substituted patients 2-month of GH-withdrawal caused significant changes in body composition, including decreased fat-free mass, skeletal muscle mass, total body water, and intracellular water content (all, p&amp;lt;0.01); but these changes almost fully recovered 1 month after reinstituting GHRT. Unexpectedly, afamin levels decreased after GH-withdrawal (p=0.03) and increased with reinstitution (p&amp;lt;0.01). Changes of afamin levels during GH-withdrawal positively correlated with changes of HOMA-IR (r=0.80; p&amp;lt;0.01) and changes of insulin (r=0.71; p=0.02).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Higher afamin levels in unsubstituted AGHD patients might indicate severe metabolic dysregulation. Significant changes accompanying GH-withdrawal and reinstitution, along with strong correlations with measures of IR, suggest that afamin could be a promising biomarker to monitor GHRT-associated changes of insulin sensitivity.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2024.1348046","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T04:39:50Z","timestamp":1707194390000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Serum afamin and its implications in adult growth hormone deficiency: a prospective GH-withdrawal study"],"prefix":"10.3389","volume":"15","author":[{"given":"Bal\u00e1zs","family":"Ratku","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajnalka","family":"L\u0151rincz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e1ra","family":"Csiha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronika","family":"Sebesty\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eszter","family":"Berta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikl\u00f3s","family":"Bodor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Endre V.","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zolt\u00e1n","family":"Szab\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariann","family":"Harangi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e1ndor","family":"Somodi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-022-01207-1","article-title":"Effects of adult growth hormone deficiency and replacement therapy on the cardiometabolic risk profile","volume":"25","author":"Ratku","year":"2022","journal-title":"Pituitary"},{"key":"B2","article-title":"Growth hormone and the metabolic syndrome","volume":"22","author":"Johannsson","year":"1999","journal-title":"J Endocrinol Invest"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-06-0699","article-title":"The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH","volume":"156","author":"van der Klaauw","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1530\/EC-18-0096","article-title":"The prevalence of the metabolic syndrome and associated cardiovascular complications in adult-onset GHD during GH replacement: a KIMS analysis","volume":"7","author":"Verhelst","year":"2018","journal-title":"Endocr Connect."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0599","article-title":"Prevalence and characteristics of the metabolic syndrome in 2479 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis","volume":"165","author":"Verhelst","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-022-01974-5","article-title":"Increased levels of plasma neudesin in adult growth hormone deficiency and their relationship with plasma liver-expressed antimicrobial peptide-2 levels: a cross-sectional study","volume":"46","author":"Vergani","year":"2023","journal-title":"J Endocrinol Invest."},{"key":"B7","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1210\/jc.2009-1326","article-title":"Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and after GH replacement","volume":"95","author":"Attanasio","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad129","article-title":"High-performance liquid chromatography-mass spectrometry-based metabolic profiling of adult growth hormone deficiency","volume":"108","author":"Yang","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1530\/EC-14-0098","article-title":"Metabolomics: a tool for the diagnosis of GH deficiency and for monitoring GH replacement","volume":"3","author":"H\u00f6ybye","year":"2014","journal-title":"Endocr Connect"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)32429-8","article-title":"Afamin is a new member of the albumin, alpha-fetoprotein, and vitamin D-binding protein gene family","volume":"269","author":"Lichenstein","year":"1994","journal-title":"J Biol Chem"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2015.04.010","article-title":"Afamin\u2013A pleiotropic glycoprotein involved in various disease states","volume":"446","author":"Dieplinger","year":"2015","journal-title":"Clin Chim Acta"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGENETICS.113.000654","article-title":"Plasma concentrations of afamin are associated with the prevalence and development of metabolic syndrome","volume":"7","author":"Kronenberg","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0201","article-title":"Plasma concentrations of afamin are associated with prevalent and incident type 2 diabetes: A pooled analysis in more than 20,000 individuals","volume":"40","author":"Kollerits","year":"2017","journal-title":"Diabetes Care"},{"key":"B14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1477-7827-12-88","article-title":"Afamin serum concentrations are associated with insulin resistance and metabolic syndrome in polycystic ovary syndrome","volume":"12","author":"Seeber","year":"2014","journal-title":"Reprod Biol Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2337\/dc11-0449","article-title":"Incidence of Diabetes Mellitus and Evolution of Glucose Parameters in Growth Hormone\u2013Deficient Subjects During Growth Hormone Replacement Therapy: A long-term observational study","volume":"35","author":"Luger","year":"2011","journal-title":"Diabetes Care"},{"key":"B16","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1530\/EJE-07-0631","article-title":"Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia","volume":"157","author":"Ho","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"B18","doi-asserted-by":"publisher","first-page":"10039","DOI":"10.1038\/s41598-017-09968-7","article-title":"Plasma biomarker proteins for detection of human growth hormone administration in athletes","volume":"7","author":"Tan","year":"2017","journal-title":"Sci Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2021-0837","article-title":"Afamin predicts the prevalence and incidence of nonalcoholic fatty liver disease","volume":"60","author":"Pitk\u00e4nen","year":"2022","journal-title":"Clin Chem Lab Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24044115","article-title":"Impaired organokine regulation in non-diabetic obese subjects: halfway to the cardiometabolic danger zone","volume":"24","author":"L\u0151rincz","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00788.x","article-title":"Noninvasive markers of liver fibrosis and inflammation in chronic hepatitis B-virus related liver disease","volume":"101","author":"Mohamadnejad","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"7175108","DOI":"10.1155\/2022\/7175108","article-title":"Association between serum afamin levels with nonalcoholic associated fatty liver disease","volume":"2022","author":"Chen","year":"2022","journal-title":"Can J Gastroenterol Hepatology."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.670425","article-title":"Serum afamin a novel marker of increased hepatic lipid content","volume":"12","author":"Kurdiova","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1530\/EJE-12-0252","article-title":"Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy","volume":"167","author":"Nishizawa","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1953","article-title":"Growth hormone deficiency and NAFLD: An overlooked and underrecognized link","volume":"6","author":"Doycheva","year":"2022","journal-title":"Hepatol Commun"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ23-0157","article-title":"Association of nonalcoholic fatty liver disease and growth hormone deficiency: a systematic review and meta-analysis","volume":"70","author":"Kong","year":"2023","journal-title":"Endocr J"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/nu15112498","article-title":"The interplay of adipokines, body composition and glucose homeostasis in pregnant women with a history of RYGB operation","volume":"15","author":"Bellach","year":"2023","journal-title":"Nutrients"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1817346","article-title":"Pathogenesis and diagnosis of growth hormone deficiency in adults","volume":"380","author":"Melmed","year":"2019","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4158\/GL-2019-0405","article-title":"American association of clinical endocrinologists and american college of endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care","volume":"25","author":"Yuen","year":"2019","journal-title":"Endocr Pract"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17072595","article-title":"Comparison of bioelectrical impedance analysis and dual energy X-ray absorptiometry for total and segmental bone mineral content with a three-compartment model","volume":"17","author":"Liao","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2012.06.015","article-title":"Afamin secreted from nonresorbing osteoclasts acts as a chemokine for preosteoblasts via the Akt-signaling pathway","volume":"51","author":"Kim","year":"2012","journal-title":"Bone"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3275\/8975","article-title":"Afamin stimulates osteoclastogenesis and bone resorption via Gi-coupled receptor and Ca2+\/calmodulin-dependent protein kinase (CaMK) pathways","volume":"36","author":"Kim","year":"2013","journal-title":"J Endocrinol Invest."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2016.06.013","article-title":"Afamin promotes glucose metabolism in papillary thyroid carcinoma","volume":"434","author":"Shen","year":"2016","journal-title":"Mol Cell Endocrinol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1530\/EJE-12-0807","article-title":"Prevalence of diabetes mellitus in 6050 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis","volume":"168","author":"Abs","year":"2013","journal-title":"Eur J Endocrinology."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/biom12010116","article-title":"Afamin levels and their correlation with oxidative and lipid parameters in non-diabetic, obese patients","volume":"12","author":"Juh\u00e1sz","year":"2022","journal-title":"Biomolecules"},{"key":"B36","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1530\/eje.1.02179","article-title":"Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults \u2013 a KIMS database analysis","volume":"155","author":"Abs","year":"2006","journal-title":"Eur J Endocrinology."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-1086","article-title":"Effects of discontinuation of growth hormone replacement in adult GH-deficient patients: a cohort study and a systematic review of the literature","volume":"174","author":"Appelman-Dijkstra","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1046\/j.1463-1326.1999.00048.x","article-title":"Unfavourable impact of growth hormone (GH) discontinuation on body composition and cholesterol profiles after the completion of height growth in GH-deficient young adults","volume":"1","author":"Kohno","year":"1999","journal-title":"Diabetes Obes Metab"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2021.08.003","article-title":"Role of growth hormone in hepatic and intestinal triglyceride-rich lipoprotein metabolism","volume":"15","author":"Maraninchi","year":"2021","journal-title":"J Clin Lipidol."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2006","article-title":"Discontinuing long-term GH replacement therapy\u2013a randomized, placebo-controlled crossover trial in adult GH deficiency","volume":"97","author":"Filipsson Nystr\u00f6m","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1844","article-title":"Common carotid intima-media thickness in growth hormone (GH)-deficient adolescents: a prospective study after GH withdrawal and restarting GH replacement","volume":"90","author":"Colao","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1998.00086.x","article-title":"Influence of hematocrit on the measurement of lipoproteins demonstrated by the example of lipoprotein(a)","volume":"54","author":"Kronenberg","year":"1998","journal-title":"Kidney Int"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa558","article-title":"Identification of proteins associated with the early restoration of insulin sensitivity after biliopancreatic diversion","volume":"105","author":"Karlsson","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B44","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.cels.2018.10.012","article-title":"Plasma proteome profiling reveals dynamics of inflammatory and lipid homeostasis markers after roux-en-Y gastric bypass surgery","volume":"7","author":"Wewer Albrechtsen","year":"2018","journal-title":"Cell Syst"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.22038\/AJP.2020.16698","article-title":"The positive effect of short-term nano-curcumin therapy on insulin resistance and serum levels of afamin in patients with metabolic syndrome","volume":"11","author":"Kheiripour","year":"2021","journal-title":"Avicenna J Phytomed."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2018.10.008","article-title":"Serum biomarkers of glucocorticoid response and safety in anti-neutrophil cytoplasmic antibody-associated vasculitis and juvenile dermatomyositis","volume":"140","author":"Conklin","year":"2018","journal-title":"Steroids"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1210\/er.2008-0027","article-title":"Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects","volume":"30","author":"M\u00f8ller","year":"2009","journal-title":"Endocrine Rev"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2013.08.016","article-title":"Analytical characterization and clinical evaluation of an enzyme-linked immunosorbent assay for measurement of afamin in human plasma","volume":"425","author":"Dieplinger","year":"2013","journal-title":"Clin Chim Acta"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2006.08.021","article-title":"Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results","volume":"152","author":"Wu","year":"2006","journal-title":"Am Heart J"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2004.037275","article-title":"Biological variation of procalcitonin in healthy individuals","volume":"50","author":"Barassi","year":"2004","journal-title":"Clin Chem"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/biom11020217","article-title":"Insulin-like growth factor-1 (IGF-1) and its monitoring in medical diagnostic and in sports","volume":"11","author":"Bailes","year":"2021","journal-title":"Biomolecules"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1530\/EC-18-0047","article-title":"Growth Hormone Research Society perspective on biomarkers of GH action in children and adults","volume":"7","author":"Johannsson","year":"2018","journal-title":"Endocr Connect"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1569402","article-title":"Lipid accumulation product: a simple and accurate index for predicting metabolic syndrome in patients with adult growth hormone deficiency","volume":"124","author":"Chan","year":"2016","journal-title":"Exp Clin Endocrinol Diabetes."},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1530\/EC-19-0159","article-title":"Serum soluble urokinase plasminogen activator receptor (suPAR) in adults with growth hormone deficiency","volume":"8","author":"H\u00f6ybye","year":"2019","journal-title":"Endocr Connect."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/biof.1628","article-title":"Plasmatic lipocalin-2 levels in chronic low-grade inflammation syndromes: Comparison between metabolic syndrome, total and partial adult growth hormone deficiency","volume":"46","author":"Curr\u00f2","year":"2020","journal-title":"Biofactors"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/biof.1444","article-title":"Plasmatic free light chains as inflammatory marker in insulin resistance: comparison of metabolic syndrome with adult growth hormone deficiency","volume":"44","author":"Basile","year":"2018","journal-title":"Biofactors"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-017-1468-1","article-title":"Oxidative stress in adult growth hormone deficiency: different plasma antioxidant patterns in comparison with metabolic syndrome","volume":"59","author":"Mancini","year":"2018","journal-title":"Endocrine"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/BF03345231","article-title":"Effects of GH and insulin-like growth factor-I on body composition","volume":"26","author":"Svensson","year":"2003","journal-title":"J Endocrinol Invest"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1348046\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T04:40:02Z","timestamp":1707194402000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1348046\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,6]]},"references-count":58,"alternative-id":["10.3389\/fendo.2024.1348046"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1348046","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,6]]},"article-number":"1348046"}}